PExA, Named Awardee in the Carcinogenic Exposure Meter Quickfire Challenge for Its Innovative Works
By MedTech Outlook | Wednesday, February 13, 2019
Erik Ekbo, CEO
Lung cancer has become an epidemic in recent years. According to statistics by Lungevity, one in sixteen people in the US are supposed to be diagnosed with lung cancer in their lifetime. Center for Disease Control and Prevention (CDC) states that smoking is the number one risk factor for lung cancer, causing about 80 to 90 percent of lung cancers in the U.S. Many healthcare companies are looking for solutions to pave the way for early detection and to provide more personalized and effective treatment of lung diseases.
PExA, a Swedish medical Technology company has been selected as the awardee of the Carcinogenic Exposure Meter Quickfire Challenge, a Lung Cancer Initiative (LCI) by Johnson & Johnson innovation at Johnson & Johnson, and Janssen Research & Development LLC. The Challenge looked for innovative approaches to measure lung damage caused by exposure to tobacco smoke.
The most distal regions of our lungs are referred to as the “small airways”, where all matter that is inhaled including bacteria, virus, along with toxic compounds from smoke ends up settling. The air sacs that account for the vast surface area needed for enough gas exchange is connected to the larger airways via millions of 2 mm airway tubes, making it the budding area for the disease. There is no non-invasive way that allows researchers or physicians to reach and examine this vital area.
PExA enables non-invasive proximal sampling, a highly relevant source for biomarker discovery, basic science and Pharma R&D in the field of respiratory medicine. The company has developed and commercialized a breakthrough technology for the non-invasive collection of proximal biomarkers. Erik Ekbo, CEO at PExA states, “We have the true potential to fundamentally change how respiratory diseases are being detected and treated today.”
PExA has been recognized as the “Top 20 MedTech Solution Providers in Europe-2018” by magazine MedicalTechOutlook. PExA will receive $250,000 in grant funding as the awardee of the Carcinogenic Exposure meter Quickfire Challenge to further advance its technology. The challenge was launched to reduce tobacco consumption by developing carcinogenic exposure meter technologies that allow smokers to view the damage caused by smoking through real-time measurement of the effect of carcinogens.